Novel Autologous Cell Therapy Shows 92% Success Rate in Treating Limbal Stem Cell Deficiency
A groundbreaking Phase I/II clinical trial demonstrates 93% manufacturing success rate for Cultivated Autologous Limbal Epithelial Cell (CALEC) transplantation, offering new hope for limbal stem cell deficiency patients.
© Copyright 2025. All Rights Reserved by MedPath